# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

> **NCT03346122** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 86 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64991524 Dose Level 1
- **DRUG:** JNJ-64991524 Dose Level 2
- **DRUG:** JNJ-64991524 Dose Level 3
- **DRUG:** JNJ-64991524 Dose Level 4
- **DRUG:** JNJ-64991524 Dose Level 5
- **DRUG:** JNJ-64991524 Dose Level 6
- **DRUG:** Placebo
- **DRUG:** JNJ-64991524 Dose Level 7
- **DRUG:** JNJ-64991524 Dose Level 8
- **DRUG:** JNJ-64991524 Dose Level 9

## Key facts

- **NCT ID:** NCT03346122
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-11-20
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2019-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346122, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03346122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*